<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Asia Pac Allergy</journal-id><journal-id journal-id-type="publisher-id">APA</journal-id><journal-title-group><journal-title>Asia Pacific Allergy</journal-title></journal-title-group><issn pub-type="ppub">2233-8276</issn><issn pub-type="epub">2233-8268</issn><publisher><publisher-name>Asia Pacific Association of Allergy, Asthma and Clinical Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3206241</article-id><article-id pub-id-type="pmid">22053308</article-id><article-id pub-id-type="doi">10.5415/apallergy.2011.1.3.123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Current Review</subject></subj-group></article-categories><title-group><article-title>Sublingual immunotherapy in allergic rhinitis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Han</surname><given-names>Doo Hee</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rhee</surname><given-names>Chae-Seo</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul 110-799, Korea.</aff><aff id="A2"><label>2</label>Graduate School of Immunology, Seoul National University College of Medicine, Seoul 110-799, Korea.</aff><aff id="A3"><label>3</label>Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul 110-799, Korea.</aff><aff id="A4"><label>4</label>Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul 110-799, Korea.</aff><author-notes><corresp>
Correspondence: Chae-Seo Rhee. Department of Otorhinolaryngology, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam 463-707, Korea. Tel: +82-31-787-7401, Fax: +82-31-787-4057, <email>csrhee@snu.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>11</day><month>10</month><year>2011</year></pub-date><volume>1</volume><issue>3</issue><fpage>123</fpage><lpage>129</lpage><history><date date-type="received"><day>04</day><month>9</month><year>2011</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Current treatment options for allergic rhinitis (AR) include allergen avoidance and environmental control, pharmacotherapy, nasal surgery and immunotherapy. Among these, immunotherapy is the only therapeutic option that modifies fundamental immunologic mechanism by inducing desensitization. Specific allergen immunotherapy has been used for 1 century since 1911 and subcutaneous immunotherapy (SCIT) has been demonstrated to be effective in asthma and AR. However, SCIT has several disadvantages such as inconvenience, invasiveness and potentially severe systemic reactions. Thus, sublingual immunotherapy (SLIT) has recently received much attention around the world as a treatment for AR and is now widely used to replace the subcutaneous route. SLIT has recently been introduced in Korea and is now available for AR treatment in the Asia-Pacific region. This review offers better understanding of SLIT for AR by summarizing published articles and our previous works regarding proposed mechanisms, indication and efficacy, safety and adverse events, and compliance.</p></abstract><kwd-group><kwd>Immunotherapy</kwd><kwd>Sublingual administration</kwd><kwd>Rhinitis</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>The incidence of allergic rhinitis (AR) in the general population is currently around 10%-25%. Medical cost for AR treatment is increasing, and considering comorbid diseases including asthma, the treatment of AR has become more than just treating the rhinitis itself [<xref ref-type="bibr" rid="B1">1</xref>]. AR treatment can be classified into 4 categories: (1) avoidance and environmental control, (2) pharmacotherapy, (3) surgical treatment and (4) immunotherapy. Avoidance and environmental control is the safest way, but these are not always feasible. Intranasal corticosteroids and oral antihistamines have been accepted to be effective with few adverse effects. However, medical therapy only reduces allergic symptoms rather than reversing basic immunologic profiles of the AR patients. Surgical treatment is usually performed to correct structural problems which can aggravate nasal allergic symptoms and reduce the effective delivery of intranasal corticosteroids.</p><p>Allergen specific immunotherapy (SIT) has been studied and used for 1 century since Noon's first report in 1911 [<xref ref-type="bibr" rid="B2">2</xref>]. SIT is the only treatment option that modified fundamental allergic mechanism by inducing desensitization. At first, SIT was used for allergic diseases caused by pollen allergen, such as hay fever or seasonal AR, however today, indications extends to hymenoptera venom, house dust mites (HDMs), animal dander and allergic diseases for fungi [<xref ref-type="bibr" rid="B3">3</xref>]. Allergen extracts are injected intradermally. For safety, dosage starts at low concentration and increases slowly. When dosage reaches to maintenance concentration, maintenance dose is injected regularly for 3-5 years.</p><p>However, subcutaneous immunotherapy (SCIT) has several disadvantages. Patients have to visit clinicians' office regularly for injection and to tolerate the injection pain, and doctors should concern side effect such as anaphylaxis. Thus, SCIT is recommended to be performed only in facilities with adequate personnel and equipment that can effectively handle anaphylactic events [<xref ref-type="bibr" rid="B4">4</xref>]. Because of these inconveniences, other allergen administration methods including intranasal, oral, sublingual routes have been developed. Among them, sublingual immunotherapy (SLIT) has been widely used in European countries replacing SCIT because SLIT has several advantages: noninvasiveness, home administration, less frequency of severe adverse reaction than SCIT. The efficacy and safety of SLIT have been studied and in 2008, British Society for Allergy and Clinical Immunology announced SLIT as safe immunotherapy for AR and asthma [<xref ref-type="bibr" rid="B5">5</xref>] and in 2009, World Allergy Organization Position Paper about SLIT described its efficacy and safety [<xref ref-type="bibr" rid="B6">6</xref>]. This article discussed the proposed mechanism, indication, efficacy according to allergen, safety and compliance of SLIT.</p><sec><title>Proposed mechanisms of SLIT</title><p>There are several studies that reported the immunologic changes of SLIT were similar to those of SCIT [<xref ref-type="bibr" rid="B7">7</xref>]. Both SLIT and SCIT are allergen specific immunotherapy, which derive 3 major immunologic changes: (1) regulation of allergen specific antibody response, (2) reduction of proinflammatory cell recruitment and activation, and (3) changes in allergen specific T cell response. In addition, we discuss about the oral (mucosal) tolerance as well as the 3 above-mentioned mechanisms.</p><sec><title>(1) Regulation of allergen specific antibody response</title><p>It is typical characteristics of allergic disease that serum allergen specific IgE binds to Fc&#x003b5;RI receptor on mast cell surface. Serum IgE level elevates in early phase of SCIT, but decreases several months after SCIT. This decline prevents seasonal rise of IgE in grass pollen allergic patients. However, early symptomatic improvement after immunotherapy does not relate to IgE level change because this change occurs in later phase of immunotherapy. Allergen specific IgG (mostly IgG1 and IgG4) rises, which relates to the clinical improvement. Also, IgA level sometimes increases [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>In SLIT, similar to SCIT, the increase of allergen specific IgG4 level and the decrease of IgE/IgG4 ratio were observed. Recent meta-analysis reported that SLIT provoked significant change of allergen specific IgG and IgG4 level [<xref ref-type="bibr" rid="B8">8</xref>] and one another meta-analysis did that allergen specific IgG4 level increased and change in IgE/IgG4 ratio related to the reduction of skin reaction to allergen in later phase of SLIT and clinical improvement [<xref ref-type="bibr" rid="B9">9</xref>]. IgG4, known as blocking antibody, could antagonize and prohibit the allergic inflammation cascade resulting from antigen recognition by IgE. Therefore, the shift from IgE to IgG4 and change of IgE/IgG4 ratio is important for successes of immunotherapy [<xref ref-type="bibr" rid="B10">10</xref>]. Allergen specific IgE level changes were controversial [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. The 2-year HDM SLIT treatment in asthmatic children did not show any differences in HDM-specific IgE between SLIT and placebo groups [<xref ref-type="bibr" rid="B11">11</xref>]. In our study on AR patients, specific IgE for <italic>Dermatophagoides farinae</italic> increased after 12-month SLIT, while specific IgE for <italic>Dermatophagoides pteronyssinus</italic> did not change significantly [<xref ref-type="bibr" rid="B12">12</xref>]. However, in grass pollen SLIT, time- and dose-dependent increases of Phleum pratense-specific serum IgE were found, indicating that the SLIT treatment had a significant allergen-specific effect on the immune system [<xref ref-type="bibr" rid="B13">13</xref>]. The change of IgA has also been reported. Antigen specific serum IgA rose in dose-dependent manner in SLIT with grass pollen allergen [<xref ref-type="bibr" rid="B13">13</xref>] and was up-regulated in SLIT with HDM allergen [<xref ref-type="bibr" rid="B14">14</xref>]. Thus, allergen specific IgG (and IgA) without any changes of IgE are thought to contribute to the clinical responses of SLIT.</p></sec><sec><title>(2) Reduction of proinflammatory cell recruitment and activation</title><p>SCIT reduces recruitment and activation of proinflammatory cells in mucosa related to allergic reaction. Recruitment and activation of mast cell, eosinophil and basophil decrease in the skin, the nasal cavity, the conjunctiva and the bronchial mucosa after allergen exposure when SCIT has been successful. SCIT induces peripheral T cell immune tolerance and regulates activation threshold of mast cell and basophil. Also, SCIT increases IL-10 production, which prohibits secretion of proinflammatory cytokines by mast cell, down-regulates functions and activities of eosinophil, and inhibits IL-5 production by Th0 and Th2 cells. Resembling these responses, SLIT decreased the level of basophil in the conjunctiva or the nasal cavity after allergen exposure. It was reported that the local or systemic eosinophil cationic protein (ECP) level was decreased in SLIT for grass pollen [<xref ref-type="bibr" rid="B15">15</xref>] and HDMs [<xref ref-type="bibr" rid="B12">12</xref>].</p></sec><sec><title>(3) Changes in allergen specific T cell response</title><p>The balance between Th1 and Th2 responses is crucial for allergic inflammation. SCIT induces Th1 response and reduces synthesis of Th2 cytokines. In grass pollen SCIT, the shift from Th2 profile to Th1 profile occurred in nasal mucosa or skin consistently although systemic change were not consistent. This results showed immunologic change is important not only in the peripheral blood but also in target organs.</p><p>It is the key step of SIT to maintain immunologic tolerance of peripheral T cell by antigen specific regulatory T cell. SCIT induces regulatory T cell, which secretes IL-10 and TGF-&#x003b2; [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. IL-10 has several immunoregulatory functions on Th1 and Th2 responses. IL-10 promotes IgG4 rather than IgE class switching, and decreases MHC class II expression and activation and migration of mast cell and eosinophil [<xref ref-type="bibr" rid="B18">18</xref>]. TGF-&#x003b2; suppresses on both Th1 and Th2 responses, contributes to generate regulatory T cell subsets and induces B-cell immunoglobulin class switching to IgA [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>T cell response in SLIT has not been fully elucidated. Some reported that SLIT with grass pollen did not have significant effect on T cell function including cytokine synthesis and cell proliferation and did not raise the counts of dendritic cell and T cell in epithelium and lamina propria [<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>]. However, other studies using HDM SLIT, showed SLIT reduces IL-13, one of the Th2 cytokines, peripheral monocyte proliferation, ECP and prolactin [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>] and induces IL-10 production [<xref ref-type="bibr" rid="B24">24</xref>]. The reduction of prolactin level could reflect that T cell activity was reduced because prolactin is produced by activated T cell.</p></sec><sec><title>(4) Induction of oral mucosal immune tolerance</title><p>During SLIT, allergens are captured through Fc&#x003b5;RI and/or other structures expressed by oral mucosal Langerhans-like DCs. DCs induce protolerogenic mechanisms in oral mucosa by the upregulation of coinhibitory molecule expression (B7H1 and B7H3) or release of IL-10 [<xref ref-type="bibr" rid="B25">25</xref>]. Allergen uptake of DCs attenuates their maturation and expression of chemokine receptor 7 (CCR7), being essential for the recruitment of DCs to peripheral lymphoid organs. Attenuated maturation and lower CCR7 expression of DCs after allergen uptake during migration to the lymphoid tissue might provide evidence of antigen presentation of DCs to T cells being performed outside local draining lymphoid tissues, ie, local contact of oral DCs with T cells in the oral mucosa [<xref ref-type="bibr" rid="B25">25</xref>]. Oral DCs are able to prime regulatory T (Treg) cells such as CD4<sup>+</sup> CD25<sup>+</sup> Foxp3<sup>+</sup> Treg cells, which increase in the oral epithelium during SLIT. Moreover, enhancement of Foxp3<sup>+</sup> Treg cells and IgG4 in peripheral blood as well as IL-10, IL-18 and signaling lymphocytic activation molecule in peripheral blood mononuclear cells was observed during SLIT [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>]. In addition, expression of programmed cell death ligand 1 on monocytes and B cells increased, while IL-4 production decreased in patients receiving pollen SLIT [<xref ref-type="bibr" rid="B28">28</xref>].</p></sec></sec><sec><title>Indications of SLIT</title><p>In 2008, Allergic Rhinitis and its Impact on Asthma (ARIA) [<xref ref-type="bibr" rid="B29">29</xref>] suggested the indications for SLIT: (1) carefully selected patients with rhinitis, conjunctivitis and/or asthma caused by pollen and mite allergy, (2) patients insufficiently controlled by conventional pharmacotherapy, (3) patients who have presented with systemic reactions during injection-specific immunotherapy, and (4) patients showing poor compliance with or refusing injections.</p><p>SIT could apply to AR if the existence of allergen specific antibody and provocation of symptoms by the same allergen are proved [<xref ref-type="bibr" rid="B30">30</xref>]. To identify specific antigen, skin prick test (SPT) is preferred rather than multiple allergen simultaneous test which has lower sensitivity than SPT. Positive SPT result usually reflects the presence of antigen specific serum IgE, however, it should be correlated with clinical symptoms or AR history of the patients.</p><p>Some conditions relating patients' characteristics as well as AR itself should be considered. Poor compliance and bad communication would make it hard to evaluate symptom, efficacy and side effects of SLIT. One study reported that SLIT in very young children aged 1 to 3 years was safe [<xref ref-type="bibr" rid="B31">31</xref>], which suggests that age limitation does not seem to exist.</p></sec><sec><title>Efficacy of SLIT</title><p>Meta-analysis have proved SLIT had therapeutic efficacy for asthma and both adult and childhood AR [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B34">34</xref>], and the ARIA group acknowledged the efficacy of SLIT on rhinitis patients for birch, cypress, grass, olive, <italic>Parietaria</italic> and HDM in 2008 [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>There are some initial studies that SLIT did not have desensitizing effect to HDM and grass pollen allergen comparing to placebo group [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>]. Moreover, SLIT had therapeutic efficacy on only severe AR and at least 3 year-treatment was required for clinical improvement [<xref ref-type="bibr" rid="B35">35</xref>]. As time goes, several studies for confirming SLIT efficacy have been conducted. One double-blind placebo-controlled (DBPC) studies including 855 patients with grass pollen AR showed moderate reduction of symptom score (16%) and medication use (28%) after 18-week treatment [<xref ref-type="bibr" rid="B37">37</xref>]. A recent meta-analysis showed that the patient with SLIT had less symptom (SMD, -0.49) and medication scores (SMD, -0.32) [<xref ref-type="bibr" rid="B8">8</xref>]. In our study of HDM SLIT in 88 patient with AR, all symptoms including nasal, eye discomfort and sleep disturbance were significantly improved 12 months after SLIT (<italic>p</italic> &#x0003c; 0.05) and a significant reduction of symptomatic medication use was observed between the first and 12 months (<italic>p</italic> &#x0003c; 0.001) [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The efficacy of SLIT in children has shown controversies. A study reported low dose allergen administration for 2 years to asthmatic children with HDM allergy did not change immunologic parameters [<xref ref-type="bibr" rid="B11">11</xref>]. In 2006, one meta-analysis for confirming efficacy of SLIT for pediatric AR patients 3 to 18 years of age showed a significant reduction in both symptoms (SMD, 0.56) and medication use (SMD, 0.76) after SLIT [<xref ref-type="bibr" rid="B38">38</xref>]. Recently, World Allergy Organization Position Paper reported that SLIT for pollen and HDM had the efficacy in children with AR &#x02265;5 years of age and might be safely used in children &#x02265;3 years of age [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>The maintaining effects after discontinuation of SLIT has not yet been fully established although those of SCIT has been acknowledged [<xref ref-type="bibr" rid="B39">39</xref>]. A study including 137 patients with HDM AR showed that a greater improvement in the 3 years of SLIT compared with the 2 years of SLIT [<xref ref-type="bibr" rid="B40">40</xref>]. In another study with 15 years observation including mono-sensitized patients to HDM, clinical benefits of SLIT persisted for 7 years in patients with 3-year SLIT and for 8 years in those with 4, 5-year SLIT [<xref ref-type="bibr" rid="B41">41</xref>]. This study suggested that a 4-year SLIT is the optimal choice in present conditions because it induces a long-lasting clinical improvement similar to that of 5-year course and greater than that of a 3-year SLIT.</p><p>Preventive effect for asthma of SLIT has been established. In a study including 113 children with hay fever limited to grass pollen, development of asthma was 3.8 times less frequent in the SLIT group than in the control group after 3-year treatment [<xref ref-type="bibr" rid="B42">42</xref>]. Another study reported that 35 patients with allergic asthma/rhinitis due to HDM underwent SLIT for 4-5 years had significantly lower presence of asthma and use of antiasthmatic medication after SLIT, whereas 25 received only drug therapy had no change [<xref ref-type="bibr" rid="B43">43</xref>]. It also has been insisted that SLIT could prevent new allergen sensitization. One study reported that new sensitization appeared in 3.1% of 3-year SLIT patients although it appeared in 34.8% of patients who received drugs alone for 3 years [<xref ref-type="bibr" rid="B44">44</xref>].</p></sec><sec><title>Safety and adverse events</title><p>One of the advantages of SLIT over SCIT is the favorable safety profile. It is the safety that the most important advantage of SLIT comparing to SCIT. SCIT sometimes induces severe adverse side effects such as anaphylaxis. One DBPC study using grass and birch allergen reported 3.3% of patients received grass allergen and 0.7% of patients received birch allergen had systemic side effect [<xref ref-type="bibr" rid="B45">45</xref>]. Postmarketing surveillance study showed 0.9% of injection, 3.7% of patients underwent SCIT had systemic side effects [<xref ref-type="bibr" rid="B46">46</xref>].</p><p>According to a comprehensive review of published DBPC study, the adverse event rates were 23% in SLIT group and 12% in placebo group, and systemic events were 17% and 12%, respectively. Adverse event occurrences were not dose dependent and severe systemic reactions were not reported [<xref ref-type="bibr" rid="B47">47</xref>]. However, one DBPC study reported treatment related adverse events, irritation of the throat, and itching sensations in the mouth and ears, increased with dose [<xref ref-type="bibr" rid="B48">48</xref>]. There was no fatal event according to the report evaluating 66 studies including 4,378 patients, 1,181,654 administrations [<xref ref-type="bibr" rid="B49">49</xref>]. Forty one of 66 studies reporting adverse events showed 1,047 adverse events during 386,149 administrations (2.7/1,000 administration). Recent meta-analysis showed local reaction such as labial, buccolingual edema, buccal pruritus or throat irritation, and systemic reactions in the upper respiratory tract and associated organs (rhinitis, conjunctivitis or rhinoconjunctivitis) were more frequent in the SLIT group than in placebo group, however, asthma or wheeze occurred in similar rates in both SLIT and placebo groups and there was no fatality. Gastrointestinal problems were more common in SLIT group, especially children [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>There were no mortality cases. Six cases with anaphylaxis, including 2 cases after using a mixture of multiple allergens, have been reported [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>]. One occurred in the treatment with latex rush protocol [<xref ref-type="bibr" rid="B52">52</xref>] and one developed after taking a dose 6-times (60 drops instead of 10 drops) greater than prescribed for HDM SLIT [<xref ref-type="bibr" rid="B53">53</xref>]. The remaining 2 occurred in the patients who had previously stopped SCIT due to severe systemic side effects [<xref ref-type="bibr" rid="B54">54</xref>]; a 13-year-old boy showed swelling of the tongue, angioedema of the eyes and generalized urticaria and a 27-year-old female experienced asthma symptoms, generalized itching and faintness with and abdominal cramps.</p><p>In our study, the incidence of adverse effects of SLIT was 52.1% (48 of 92 patients) during first 30 days, up-dosing phase [<xref ref-type="bibr" rid="B55">55</xref>]. Aggravation of AR symptoms was the most common adverse events during this phase. After 6 months or more, 13 patients (14.1%) experienced temporary adverse events such aggravation of symptoms, itching sensation in the oral cavity/lips/eyes/skin, gastrointestinal symptoms and breathing discomfort. However, these adverse events subsided spontaneously without medication. None of the patients needed to visit an emergency room.</p><p>Safety of SLIT in younger children has been studied. One study involving 65 children aged 3-7 years showed that side effects including urticaria, oral pruritus and gastrointestinal problem in children younger than 5 years were not severer than those in children aged 5-7 years [<xref ref-type="bibr" rid="B56">56</xref>]. Another study on 126 pediatric patients, aged 3-5 years, confirmed that SLIT is also safe in children under the age of 5 years [<xref ref-type="bibr" rid="B57">57</xref>]. Nine side effects in 7 children (5.6% patients and 0.2/1,000 doses) were reported and all side effects occurred during up-dosing phase: 6 gastrointestinal side effects, 2 oral itching and 1 mild abdominal pain. All problems were solved by reducing dosage. The other study showed multiple allergen SLIT in children did not have more risk of adverse reaction than mono-allergen SLIT [<xref ref-type="bibr" rid="B58">58</xref>].</p></sec><sec><title>Compliance of SLIT</title><p>Compliance is critical problem for continuing SLIT because patients administer allergen by themselves or their parents. The drop-out rates which conducted in European countries were 5%-30% in treated subjects [<xref ref-type="bibr" rid="B59">59</xref>-<xref ref-type="bibr" rid="B62">62</xref>]. In Korea, the drop-out rate of our series for 6 months were 31%, which was relatively high [<xref ref-type="bibr" rid="B55">55</xref>]. The most common reason of drop-out was inability to take medication according to schedule. Thus, convenient allergen formula and application schedule needs to be developed, and proper and prudent management of the patients is needed to reduce the drop-out rate.</p></sec></sec><sec><title>CONCLUSION</title><p>SLIT has been establishing its role for AR. SLIT could be adopted for both adult and children patients with AR for pollen or HDM with safety. Long-term use of SLIT could change immunologic profiles. SLIT as well as SCIT does not make only clinical symptom improve but also prevents poly-sensitization and development of asthma. Also, risk of severe or fatal adverse events seemed to be much less than SCIT.</p><p>However, there are still many unsolved problem. The duration and optimal dosage of SLIT are not well established. The effect duration after discontinuance of SLIT should be investigated more. The effect of SLIT in poly-sensitized patients and appropriate dose interval are still uncertain. Also, many of studies about SLIT have been conducted in European countries for Caucasian patients. Thus, further SLIT studies in Asia-Pacific region are needed.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togias</surname><given-names>A</given-names></name></person-group><article-title>Rhinitis and asthma: evidence for respiratory system integration</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>111</volume><fpage>1171</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">12789212</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noon</surname><given-names>L</given-names></name></person-group><article-title>Prophylactic inoculation against hay fever</article-title><source>Lancet</source><year>1911</year><volume>1</volume><fpage>1572</fpage><lpage>1573</lpage></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>SG</given-names></name><name><surname>Evans</surname><given-names>R</given-names><suffix>3rd</suffix></name></person-group><article-title>Allergen immunotherapy in historical perspective</article-title><source>Clin Allergy Immunol</source><year>2004</year><volume>18</volume><fpage>1</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">15042906</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><collab>Joint Task Force on Practice Parameters</collab><collab>American Academy of Allergy, Asthma and Immunology</collab><collab>American College of Allergy, Asthma and Immunology</collab><collab>Joint Council of Allergy, Asthma and Immunology</collab><article-title>Allergen immunotherapy: a practice parameter second update</article-title><source>J Allergy Clin Immunol</source><year>2007</year><volume>120</volume><fpage>S25</fpage><lpage>S85</lpage><pub-id pub-id-type="pmid">17765078</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scadding</surname><given-names>GK</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Mirakian</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>NS</given-names></name><name><surname>Leech</surname><given-names>SC</given-names></name><name><surname>Farooque</surname><given-names>S</given-names></name><name><surname>Ryan</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>SM</given-names></name><name><surname>Clark</surname><given-names>AT</given-names></name><name><surname>Dixon</surname><given-names>TA</given-names></name><name><surname>Jolles</surname><given-names>SR</given-names></name><name><surname>Siddique</surname><given-names>N</given-names></name><name><surname>Cullinan</surname><given-names>P</given-names></name><name><surname>Howarth</surname><given-names>PH</given-names></name><name><surname>Nasser</surname><given-names>SM</given-names></name></person-group><article-title>BSACI guidelines for the management of allergic and non-allergic rhinitis</article-title><source>Clin Exp Allergy</source><year>2008</year><volume>38</volume><fpage>19</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">18081563</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Casale</surname><given-names>T</given-names></name><name><surname>Lockey</surname><given-names>RF</given-names></name><name><surname>Baena-Cagnani</surname><given-names>CE</given-names></name><name><surname>Pawankar</surname><given-names>R</given-names></name><name><surname>Potter</surname><given-names>PC</given-names></name><name><surname>Bousquet</surname><given-names>PJ</given-names></name><name><surname>Cox</surname><given-names>LS</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Nelson</surname><given-names>HS</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Brozek</surname><given-names>JL</given-names></name><name><surname>Compalati</surname><given-names>E</given-names></name><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Delgado</surname><given-names>L</given-names></name><name><surname>van Wijk</surname><given-names>RG</given-names></name><name><surname>Gower</surname><given-names>RG</given-names></name><name><surname>Ledford</surname><given-names>DK</given-names></name><name><surname>Filho</surname><given-names>NR</given-names></name><name><surname>Valovirta</surname><given-names>EJ</given-names></name><name><surname>Yusuf</surname><given-names>OM</given-names></name><name><surname>Zuberbier</surname><given-names>T</given-names></name><name><surname>Akhanda</surname><given-names>W</given-names></name><name><surname>Almarales</surname><given-names>RC</given-names></name><name><surname>Ansotegui</surname><given-names>I</given-names></name><name><surname>Bonifazi</surname><given-names>F</given-names></name><name><surname>Ceuppens</surname><given-names>J</given-names></name><name><surname>Chivato</surname><given-names>T</given-names></name><name><surname>Dimova</surname><given-names>D</given-names></name><name><surname>Dumitrascu</surname><given-names>D</given-names></name><name><surname>Fontana</surname><given-names>L</given-names></name><name><surname>Katelaris</surname><given-names>CH</given-names></name><name><surname>Kaulsay</surname><given-names>R</given-names></name><name><surname>Kuna</surname><given-names>P</given-names></name><name><surname>Larenas-Linnemann</surname><given-names>D</given-names></name><name><surname>Manoussakis</surname><given-names>M</given-names></name><name><surname>Nekam</surname><given-names>K</given-names></name><name><surname>Nunes</surname><given-names>C</given-names></name><name><surname>O'Hehir</surname><given-names>R</given-names></name><name><surname>Olaguibel</surname><given-names>JM</given-names></name><name><surname>Onder</surname><given-names>NB</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Priftanji</surname><given-names>A</given-names></name><name><surname>Puy</surname><given-names>R</given-names></name><name><surname>Sarmiento</surname><given-names>L</given-names></name><name><surname>Scadding</surname><given-names>G</given-names></name><name><surname>Schmid-Grendelmeier</surname><given-names>P</given-names></name><name><surname>Seberova</surname><given-names>E</given-names></name><name><surname>Sepiashvili</surname><given-names>R</given-names></name><name><surname>Sol&#x000e9;</surname><given-names>D</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name><name><surname>Tomino</surname><given-names>C</given-names></name><name><surname>Toskala</surname><given-names>E</given-names></name><name><surname>Van Beever</surname><given-names>H</given-names></name><name><surname>Vieths</surname><given-names>S</given-names></name></person-group><article-title>Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009</article-title><source>Allergy</source><year>2009</year><volume>64</volume><issue>Suppl 91</issue><fpage>1</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">20041860</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moingeon</surname><given-names>P</given-names></name><name><surname>Batard</surname><given-names>T</given-names></name><name><surname>Fadel</surname><given-names>R</given-names></name><name><surname>Frati</surname><given-names>F</given-names></name><name><surname>Sieber</surname><given-names>J</given-names></name><name><surname>Van Overtvelt</surname><given-names>L</given-names></name></person-group><article-title>Immune mechanisms of allergen-specific sublingual immunotherapy</article-title><source>Allergy</source><year>2006</year><volume>61</volume><fpage>151</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">16409190</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radulovic</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>D</given-names></name><name><surname>Calderon</surname><given-names>M</given-names></name><name><surname>Durham</surname><given-names>S</given-names></name></person-group><article-title>Systematic reviews of sublingual immunotherapy (SLIT)</article-title><source>Allergy</source><year>2011</year><volume>66</volume><fpage>740</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">21443635</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>DR</given-names></name><name><surname>Lima</surname><given-names>MT</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name></person-group><article-title>Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis</article-title><source>Allergy</source><year>2005</year><volume>60</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15575924</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scadding</surname><given-names>G</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name></person-group><article-title>Mechanisms of sublingual immunotherapy</article-title><source>Immunol Allergy Clin North Am</source><year>2011</year><volume>31</volume><fpage>191</fpage><lpage>209</lpage><fpage>viii</fpage><pub-id pub-id-type="pmid">21530814</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajno</surname><given-names>GB</given-names></name><name><surname>Morabito</surname><given-names>L</given-names></name><name><surname>Barberio</surname><given-names>G</given-names></name><name><surname>Parmiani</surname><given-names>S</given-names></name></person-group><article-title>Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study</article-title><source>Allergy</source><year>2000</year><volume>55</volume><fpage>842</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">11003448</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Han</surname><given-names>DH</given-names></name><name><surname>Moon</surname><given-names>IJ</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Min</surname><given-names>YG</given-names></name><name><surname>Rhee</surname><given-names>CS</given-names></name></person-group><article-title>Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results</article-title><source>Am J Rhinol Allergy</source><year>2010</year><volume>24</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">20819465</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malling</surname><given-names>HJ</given-names></name><name><surname>Lund</surname><given-names>L</given-names></name><name><surname>Ipsen</surname><given-names>H</given-names></name><name><surname>Poulsen</surname><given-names>L</given-names></name></person-group><article-title>Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets</article-title><source>J Investig Allergol Clin Immunol</source><year>2006</year><volume>16</volume><fpage>162</fpage><lpage>168</lpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahceciler</surname><given-names>NN</given-names></name><name><surname>Arikan</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>Blaser</surname><given-names>K</given-names></name><name><surname>Barlan</surname><given-names>IB</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name></person-group><article-title>Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites</article-title><source>Int Arch Allergy Immunol</source><year>2005</year><volume>136</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">15722639</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>F</given-names></name><name><surname>Sensi</surname><given-names>L</given-names></name><name><surname>Frati</surname><given-names>F</given-names></name><name><surname>Senna</surname><given-names>GE</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Parmiani</surname><given-names>S</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name></person-group><article-title>Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications</article-title><source>Allergy</source><year>2001</year><volume>56</volume><fpage>1091</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">11703225</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passalacqua</surname><given-names>G</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name></person-group><article-title>Allergic rhinitis and its impact on asthma update: allergen immunotherapy</article-title><source>J Allergy Clin Immunol</source><year>2007</year><volume>119</volume><fpage>881</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">17418661</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>Verhagen</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Karamloo</surname><given-names>F</given-names></name><name><surname>Karagiannidis</surname><given-names>C</given-names></name><name><surname>Crameri</surname><given-names>R</given-names></name><name><surname>Thunberg</surname><given-names>S</given-names></name><name><surname>Deniz</surname><given-names>G</given-names></name><name><surname>Valenta</surname><given-names>R</given-names></name><name><surname>Fiebig</surname><given-names>H</given-names></name><name><surname>Kegel</surname><given-names>C</given-names></name><name><surname>Disch</surname><given-names>R</given-names></name><name><surname>Schmidt-Weber</surname><given-names>CB</given-names></name><name><surname>Blaser</surname><given-names>K</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name></person-group><article-title>Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><fpage>1567</fpage><lpage>1575</lpage><pub-id pub-id-type="pmid">15173208</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akdis</surname><given-names>CA</given-names></name><name><surname>Blesken</surname><given-names>T</given-names></name><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>W&#x000fc;thrich</surname><given-names>B</given-names></name><name><surname>Blaser</surname><given-names>K</given-names></name></person-group><article-title>Role of interleukin 10 in specific immunotherapy</article-title><source>J Clin Invest</source><year>1998</year><volume>102</volume><fpage>98</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">9649562</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jutel</surname><given-names>M</given-names></name><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>Budak</surname><given-names>F</given-names></name><name><surname>Aebischer-Casaulta</surname><given-names>C</given-names></name><name><surname>Wrzyszcz</surname><given-names>M</given-names></name><name><surname>Blaser</surname><given-names>K</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name></person-group><article-title>IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy</article-title><source>Eur J Immunol</source><year>2003</year><volume>33</volume><fpage>1205</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">12731045</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vourdas</surname><given-names>D</given-names></name><name><surname>Syrigou</surname><given-names>E</given-names></name><name><surname>Potamianou</surname><given-names>P</given-names></name><name><surname>Carat</surname><given-names>F</given-names></name><name><surname>Batard</surname><given-names>T</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>C</given-names></name><name><surname>Papageorgiou</surname><given-names>PS</given-names></name></person-group><article-title>Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization</article-title><source>Allergy</source><year>1998</year><volume>53</volume><fpage>662</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">9700035</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolinck-Werninghaus</surname><given-names>C</given-names></name><name><surname>Kopp</surname><given-names>M</given-names></name><name><surname>Liebke</surname><given-names>C</given-names></name><name><surname>Lange</surname><given-names>J</given-names></name><name><surname>Wahn</surname><given-names>U</given-names></name><name><surname>Niggemann</surname><given-names>B</given-names></name></person-group><article-title>Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen</article-title><source>Int Arch Allergy Immunol</source><year>2005</year><volume>136</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">15650310</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ippoliti</surname><given-names>F</given-names></name><name><surname>De Santis</surname><given-names>W</given-names></name><name><surname>Volterrani</surname><given-names>A</given-names></name><name><surname>Lenti</surname><given-names>L</given-names></name><name><surname>Canitano</surname><given-names>N</given-names></name><name><surname>Lucarelli</surname><given-names>S</given-names></name><name><surname>Frediani</surname><given-names>T</given-names></name></person-group><article-title>Immunomodulation during sublingual therapy in allergic children</article-title><source>Pediatr Allergy Immunol</source><year>2003</year><volume>14</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">12787302</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenoglio</surname><given-names>D</given-names></name><name><surname>Puppo</surname><given-names>F</given-names></name><name><surname>Cirillo</surname><given-names>I</given-names></name><name><surname>Vizzaccaro</surname><given-names>A</given-names></name><name><surname>Ferrera</surname><given-names>A</given-names></name><name><surname>Tosca</surname><given-names>MA</given-names></name><name><surname>Marseglia</surname><given-names>G</given-names></name><name><surname>Ciprandi</surname><given-names>G</given-names></name></person-group><article-title>Sublingual specific immunotherapy reduces PBMC proliferations</article-title><source>Eur Ann Allergy Clin Immunol</source><year>2005</year><volume>37</volume><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">15916016</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciprandi</surname><given-names>G</given-names></name><name><surname>Fenoglio</surname><given-names>D</given-names></name><name><surname>Cirillo</surname><given-names>I</given-names></name><name><surname>Vizzaccaro</surname><given-names>A</given-names></name><name><surname>Ferrera</surname><given-names>A</given-names></name><name><surname>Tosca</surname><given-names>MA</given-names></name><name><surname>Puppo</surname><given-names>F</given-names></name></person-group><article-title>Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report</article-title><source>Ann Allergy Asthma Immunol</source><year>2005</year><volume>95</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16095140</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novak</surname><given-names>N</given-names></name><name><surname>Bieber</surname><given-names>T</given-names></name><name><surname>Allam</surname><given-names>JP</given-names></name></person-group><article-title>Immunological mechanisms of sublingual allergen-specific immunotherapy</article-title><source>Allergy</source><year>2011</year><volume>66</volume><fpage>733</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">21251016</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohle</surname><given-names>B</given-names></name><name><surname>Kinaciyan</surname><given-names>T</given-names></name><name><surname>Gerstmayr</surname><given-names>M</given-names></name><name><surname>Radakovics</surname><given-names>A</given-names></name><name><surname>Jahn-Schmid</surname><given-names>B</given-names></name><name><surname>Ebner</surname><given-names>C</given-names></name></person-group><article-title>Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation</article-title><source>J Allergy Clin Immunol</source><year>2007</year><volume>120</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">17681368</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savolainen</surname><given-names>J</given-names></name><name><surname>Nieminen</surname><given-names>K</given-names></name><name><surname>Laaksonen</surname><given-names>K</given-names></name><name><surname>Laiho</surname><given-names>T</given-names></name><name><surname>Jacobsen</surname><given-names>L</given-names></name><name><surname>Lahesmaa</surname><given-names>R</given-names></name><name><surname>Terho</surname><given-names>EO</given-names></name><name><surname>Valovirta</surname><given-names>E</given-names></name></person-group><article-title>Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy</article-title><source>Allergy</source><year>2007</year><volume>62</volume><fpage>949</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">17620074</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piconi</surname><given-names>S</given-names></name><name><surname>Trabattoni</surname><given-names>D</given-names></name><name><surname>Rainone</surname><given-names>V</given-names></name><name><surname>Borgonovo</surname><given-names>L</given-names></name><name><surname>Passerini</surname><given-names>S</given-names></name><name><surname>Rizzardini</surname><given-names>G</given-names></name><name><surname>Frati</surname><given-names>F</given-names></name><name><surname>Iemoli</surname><given-names>E</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name></person-group><article-title>Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4</article-title><source>J Immunol</source><year>2010</year><volume>185</volume><fpage>7723</fpage><lpage>7730</lpage><pub-id pub-id-type="pmid">21076061</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Khaltaev</surname><given-names>N</given-names></name><name><surname>Cruz</surname><given-names>AA</given-names></name><name><surname>Denburg</surname><given-names>J</given-names></name><name><surname>Fokkens</surname><given-names>WJ</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name><name><surname>Zuberbier</surname><given-names>T</given-names></name><name><surname>Baena-Cagnani</surname><given-names>CE</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>van Weel</surname><given-names>C</given-names></name><name><surname>Agache</surname><given-names>I</given-names></name><name><surname>A&#x000ef;t-Khaled</surname><given-names>N</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Blaiss</surname><given-names>MS</given-names></name><name><surname>Bonini</surname><given-names>S</given-names></name><name><surname>Boulet</surname><given-names>LP</given-names></name><name><surname>Bousquet</surname><given-names>PJ</given-names></name><name><surname>Camargos</surname><given-names>P</given-names></name><name><surname>Carlsen</surname><given-names>KH</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Custovic</surname><given-names>A</given-names></name><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Demoly</surname><given-names>P</given-names></name><name><surname>Douagui</surname><given-names>H</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>van Wijk</surname><given-names>RG</given-names></name><name><surname>Kalayci</surname><given-names>O</given-names></name><name><surname>Kaliner</surname><given-names>MA</given-names></name><name><surname>Kim</surname><given-names>YY</given-names></name><name><surname>Kowalski</surname><given-names>ML</given-names></name><name><surname>Kuna</surname><given-names>P</given-names></name><name><surname>Le</surname><given-names>LT</given-names></name><name><surname>Lemiere</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lockey</surname><given-names>RF</given-names></name><name><surname>Mavale-Manuel</surname><given-names>S</given-names></name><name><surname>Meltzer</surname><given-names>EO</given-names></name><name><surname>Mohammad</surname><given-names>Y</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Naclerio</surname><given-names>R</given-names></name><name><surname>O'Hehir</surname><given-names>RE</given-names></name><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Ouedraogo</surname><given-names>S</given-names></name><name><surname>Palkonen</surname><given-names>S</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name><name><surname>Pawankar</surname><given-names>R</given-names></name><name><surname>Popov</surname><given-names>TA</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Rosado-Pinto</surname><given-names>J</given-names></name><name><surname>Scadding</surname><given-names>GK</given-names></name><name><surname>Simons</surname><given-names>FE</given-names></name><name><surname>Toskala</surname><given-names>E</given-names></name><name><surname>Valovirta</surname><given-names>E</given-names></name><name><surname>van Cauwenberge</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Wickman</surname><given-names>M</given-names></name><name><surname>Yawn</surname><given-names>BP</given-names></name><name><surname>Yorgancioglu</surname><given-names>A</given-names></name><name><surname>Yusuf</surname><given-names>OM</given-names></name><name><surname>Zar</surname><given-names>H</given-names></name><name><surname>Annesi-Maesano</surname><given-names>I</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Ben Kheder</surname><given-names>A</given-names></name><name><surname>Boakye</surname><given-names>DA</given-names></name><name><surname>Bouchard</surname><given-names>J</given-names></name><name><surname>Burney</surname><given-names>P</given-names></name><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Chan-Yeung</surname><given-names>M</given-names></name><name><surname>Chavannes</surname><given-names>NH</given-names></name><name><surname>Chuchalin</surname><given-names>A</given-names></name><name><surname>Dolen</surname><given-names>WK</given-names></name><name><surname>Emuzyte</surname><given-names>R</given-names></name><name><surname>Grouse</surname><given-names>L</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Johnston</surname><given-names>SL</given-names></name><name><surname>Keith</surname><given-names>PK</given-names></name><name><surname>Kemp</surname><given-names>JP</given-names></name><name><surname>Klossek</surname><given-names>JM</given-names></name><name><surname>Larenas-Linnemann</surname><given-names>D</given-names></name><name><surname>Lipworth</surname><given-names>B</given-names></name><name><surname>Malo</surname><given-names>JL</given-names></name><name><surname>Marshall</surname><given-names>GD</given-names></name><name><surname>Naspitz</surname><given-names>C</given-names></name><name><surname>Nekam</surname><given-names>K</given-names></name><name><surname>Niggemann</surname><given-names>B</given-names></name><name><surname>Nizankowska-Mogilnicka</surname><given-names>E</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Orru</surname><given-names>MP</given-names></name><name><surname>Potter</surname><given-names>P</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stoloff</surname><given-names>SW</given-names></name><name><surname>Vandenplas</surname><given-names>O</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name></person-group><article-title>Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA<sup>2</sup>LEN and AllerGen)</article-title><source>Allergy</source><year>2008</year><volume>63</volume><issue>Suppl 86</issue><fpage>8</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">18331513</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>W&#x000fc;thrich</surname><given-names>B</given-names></name><name><surname>Bucher</surname><given-names>C</given-names></name><name><surname>J&#x000f6;rg</surname><given-names>W</given-names></name><name><surname>Bircher</surname><given-names>A</given-names></name><name><surname>Eng</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>Y</given-names></name><name><surname>Schnyder</surname><given-names>F</given-names></name><name><surname>Eigenmann</surname><given-names>P</given-names></name><name><surname>Senti</surname><given-names>G</given-names></name></person-group><article-title>Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen</article-title><source>J Investig Allergol Clin Immunol</source><year>2003</year><volume>13</volume><fpage>145</fpage><lpage>148</lpage></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostinis</surname><given-names>F</given-names></name><name><surname>Tellarini</surname><given-names>L</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Falagiani</surname><given-names>P</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name></person-group><article-title>Safety of sublingual immunotherapy with a monomeric allergoid in very young children</article-title><source>Allergy</source><year>2005</year><volume>60</volume><fpage>133</fpage><pub-id pub-id-type="pmid">15575951</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olagu&#x000ed;bel</surname><given-names>JM</given-names></name><name><surname>Alvarez Puebla</surname><given-names>MJ</given-names></name></person-group><article-title>Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis</article-title><source>J Investig Allergol Clin Immunol</source><year>2005</year><volume>15</volume><fpage>9</fpage><lpage>16</lpage></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penagos</surname><given-names>M</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name><name><surname>Compalati</surname><given-names>E</given-names></name><name><surname>Baena-Cagnani</surname><given-names>CE</given-names></name><name><surname>Orozco</surname><given-names>S</given-names></name><name><surname>Pedroza</surname><given-names>A</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name></person-group><article-title>Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age</article-title><source>Chest</source><year>2008</year><volume>133</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">17951626</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Bona</surname><given-names>D</given-names></name><name><surname>Plaia</surname><given-names>A</given-names></name><name><surname>Scafidi</surname><given-names>V</given-names></name><name><surname>Leto-Barone</surname><given-names>MS</given-names></name><name><surname>Di Lorenzo</surname><given-names>G</given-names></name></person-group><article-title>Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>126</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">20674964</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bufe</surname><given-names>A</given-names></name><name><surname>Ziegler-Kirbach</surname><given-names>E</given-names></name><name><surname>Stoeckmann</surname><given-names>E</given-names></name><name><surname>Heidemann</surname><given-names>P</given-names></name><name><surname>Gehlhar</surname><given-names>K</given-names></name><name><surname>Holland-Letz</surname><given-names>T</given-names></name><name><surname>Braun</surname><given-names>W</given-names></name></person-group><article-title>Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study</article-title><source>Allergy</source><year>2004</year><volume>59</volume><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">15080830</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guez</surname><given-names>S</given-names></name><name><surname>Vatrinet</surname><given-names>C</given-names></name><name><surname>Fadel</surname><given-names>R</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>C</given-names></name></person-group><article-title>House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study</article-title><source>Allergy</source><year>2000</year><volume>55</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">10782522</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Yang</surname><given-names>WH</given-names></name><name><surname>Pedersen</surname><given-names>MR</given-names></name><name><surname>Johansen</surname><given-names>N</given-names></name><name><surname>Rak</surname><given-names>S</given-names></name></person-group><article-title>Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis</article-title><source>J Allergy Clin Immunol</source><year>2006</year><volume>117</volume><fpage>802</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">16630937</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penagos</surname><given-names>M</given-names></name><name><surname>Compalati</surname><given-names>E</given-names></name><name><surname>Tarantini</surname><given-names>F</given-names></name><name><surname>Baena-Cagnani</surname><given-names>R</given-names></name><name><surname>Huerta</surname><given-names>J</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name></person-group><article-title>Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials</article-title><source>Ann Allergy Asthma Immunol</source><year>2006</year><volume>97</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">16937742</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Lockey</surname><given-names>R</given-names></name><name><surname>Malling</surname><given-names>HJ</given-names></name></person-group><article-title>Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper</article-title><source>J Allergy Clin Immunol</source><year>1998</year><volume>102</volume><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">9802362</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahamiler</surname><given-names>R</given-names></name><name><surname>Saritzali</surname><given-names>G</given-names></name><name><surname>Canakcioglu</surname><given-names>S</given-names></name></person-group><article-title>Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis</article-title><source>Laryngoscope</source><year>2007</year><volume>117</volume><fpage>965</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">17545861</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marogna</surname><given-names>M</given-names></name><name><surname>Spadolini</surname><given-names>I</given-names></name><name><surname>Massolo</surname><given-names>A</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name></person-group><article-title>Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>126</volume><fpage>969</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">20934206</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novembre</surname><given-names>E</given-names></name><name><surname>Galli</surname><given-names>E</given-names></name><name><surname>Landi</surname><given-names>F</given-names></name><name><surname>Caffarelli</surname><given-names>C</given-names></name><name><surname>Pifferi</surname><given-names>M</given-names></name><name><surname>De Marco</surname><given-names>E</given-names></name><name><surname>Burastero</surname><given-names>SE</given-names></name><name><surname>Calori</surname><given-names>G</given-names></name><name><surname>Benetti</surname><given-names>L</given-names></name><name><surname>Bonazza</surname><given-names>P</given-names></name><name><surname>Puccinelli</surname><given-names>P</given-names></name><name><surname>Parmiani</surname><given-names>S</given-names></name><name><surname>Bernardini</surname><given-names>R</given-names></name><name><surname>Vierucci</surname><given-names>A</given-names></name></person-group><article-title>Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis</article-title><source>J Allergy Clin Immunol</source><year>2004</year><volume>114</volume><fpage>851</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">15480326</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Rienzo</surname><given-names>V</given-names></name><name><surname>Marcucci</surname><given-names>F</given-names></name><name><surname>Puccinelli</surname><given-names>P</given-names></name><name><surname>Parmiani</surname><given-names>S</given-names></name><name><surname>Frati</surname><given-names>F</given-names></name><name><surname>Sensi</surname><given-names>L</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name></person-group><article-title>Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study</article-title><source>Clin Exp Allergy</source><year>2003</year><volume>33</volume><fpage>206</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">12580913</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marogna</surname><given-names>M</given-names></name><name><surname>Tomassetti</surname><given-names>D</given-names></name><name><surname>Bernasconi</surname><given-names>A</given-names></name><name><surname>Colombo</surname><given-names>F</given-names></name><name><surname>Massolo</surname><given-names>A</given-names></name><name><surname>Businco</surname><given-names>AD</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name><name><surname>Tripodi</surname><given-names>S</given-names></name></person-group><article-title>Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study</article-title><source>Ann Allergy Asthma Immunol</source><year>2008</year><volume>101</volume><fpage>206</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">18727478</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winther</surname><given-names>L</given-names></name><name><surname>Malling</surname><given-names>HJ</given-names></name><name><surname>Mosbech</surname><given-names>H</given-names></name></person-group><article-title>Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects</article-title><source>Allergy</source><year>2000</year><volume>55</volume><fpage>827</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">11003446</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>C</given-names></name><name><surname>Cuesta-Herranz</surname><given-names>J</given-names></name><name><surname>Fern&#x000e1;ndez-T&#x000e1;vora</surname><given-names>L</given-names></name><name><surname>Alvarez-Cuesta</surname><given-names>E</given-names></name></person-group><article-title>Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases</article-title><source>Clin Exp Allergy</source><year>2004</year><volume>34</volume><fpage>527</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">15080803</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gidaro</surname><given-names>GB</given-names></name><name><surname>Marcucci</surname><given-names>F</given-names></name><name><surname>Sensi</surname><given-names>L</given-names></name><name><surname>Incorvaia</surname><given-names>C</given-names></name><name><surname>Frati</surname><given-names>F</given-names></name><name><surname>Ciprandi</surname><given-names>G</given-names></name></person-group><article-title>The safety of sublingual-swallow immunotherapy: an analysis of published studies</article-title><source>Clin Exp Allergy</source><year>2005</year><volume>35</volume><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">15898976</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleine-Tebbe</surname><given-names>J</given-names></name><name><surname>Ribel</surname><given-names>M</given-names></name><name><surname>Herold</surname><given-names>DA</given-names></name></person-group><article-title>Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial</article-title><source>Allergy</source><year>2006</year><volume>61</volume><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">16409193</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>LS</given-names></name><name><surname>Larenas Linnemann</surname><given-names>D</given-names></name><name><surname>Nolte</surname><given-names>H</given-names></name><name><surname>Weldon</surname><given-names>D</given-names></name><name><surname>Finegold</surname><given-names>I</given-names></name><name><surname>Nelson</surname><given-names>HS</given-names></name></person-group><article-title>Sublingual immunotherapy: a comprehensive review</article-title><source>J Allergy Clin Immunol</source><year>2006</year><volume>117</volume><fpage>1021</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">16675328</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunsky</surname><given-names>EH</given-names></name><name><surname>Goldstein</surname><given-names>MF</given-names></name><name><surname>Dvorin</surname><given-names>DJ</given-names></name><name><surname>Belecanech</surname><given-names>GA</given-names></name></person-group><article-title>Anaphylaxis to sublingual immunotherapy</article-title><source>Allergy</source><year>2006</year><volume>61</volume><fpage>1235</fpage><pub-id pub-id-type="pmid">16942576</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eifan</surname><given-names>AO</given-names></name><name><surname>Keles</surname><given-names>S</given-names></name><name><surname>Bahceciler</surname><given-names>NN</given-names></name><name><surname>Barlan</surname><given-names>IB</given-names></name></person-group><article-title>Anaphylaxis to multiple pollen allergen sublingual immunotherapy</article-title><source>Allergy</source><year>2007</year><volume>62</volume><fpage>567</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">17313400</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antico</surname><given-names>A</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Crema</surname><given-names>A</given-names></name></person-group><article-title>Anaphylaxis by latex sublingual immunotherapy</article-title><source>Allergy</source><year>2006</year><volume>61</volume><fpage>1236</fpage><lpage>1237</lpage><pub-id pub-id-type="pmid">16942577</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blazowski</surname><given-names>L</given-names></name></person-group><article-title>Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose</article-title><source>Allergy</source><year>2008</year><volume>63</volume><fpage>374</fpage><pub-id pub-id-type="pmid">18076729</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>H</given-names></name><name><surname>Bijl</surname><given-names>A</given-names></name></person-group><article-title>Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet</article-title><source>Allergy</source><year>2009</year><volume>64</volume><fpage>963</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">19222420</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>DH</given-names></name><name><surname>Mo</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Min</surname><given-names>YG</given-names></name><name><surname>Rhee</surname><given-names>CS</given-names></name></person-group><article-title>Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites</article-title><source>Clin Exp Otorhinolaryngol</source><year>2009</year><volume>2</volume><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">19784406</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiocchi</surname><given-names>A</given-names></name><name><surname>Pajno</surname><given-names>G</given-names></name><name><surname>La Grutta</surname><given-names>S</given-names></name><name><surname>Pezzuto</surname><given-names>F</given-names></name><name><surname>Incorvaia</surname><given-names>C</given-names></name><name><surname>Sensi</surname><given-names>L</given-names></name><name><surname>Marcucci</surname><given-names>F</given-names></name><name><surname>Frati</surname><given-names>F</given-names></name></person-group><article-title>Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years</article-title><source>Ann Allergy Asthma Immunol</source><year>2005</year><volume>95</volume><fpage>254</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">16200816</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rienzo</surname><given-names>VD</given-names></name><name><surname>Minelli</surname><given-names>M</given-names></name><name><surname>Musarra</surname><given-names>A</given-names></name><name><surname>Sambugaro</surname><given-names>R</given-names></name><name><surname>Pecora</surname><given-names>S</given-names></name><name><surname>Canonica</surname><given-names>WG</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name></person-group><article-title>Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years</article-title><source>Clin Exp Allergy</source><year>2005</year><volume>35</volume><fpage>560</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">15898975</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostinis</surname><given-names>F</given-names></name><name><surname>Foglia</surname><given-names>C</given-names></name><name><surname>Landi</surname><given-names>M</given-names></name><name><surname>Cottini</surname><given-names>M</given-names></name><name><surname>Lombardi</surname><given-names>C</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name></person-group><article-title>The safety of sublingual immunotherapy with one or multiple pollen allergens in children</article-title><source>Allergy</source><year>2008</year><volume>63</volume><fpage>1637</fpage><lpage>1639</lpage><pub-id pub-id-type="pmid">19032238</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombardi</surname><given-names>C</given-names></name><name><surname>Gani</surname><given-names>F</given-names></name><name><surname>Landi</surname><given-names>M</given-names></name><name><surname>Falagiani</surname><given-names>P</given-names></name><name><surname>Bruno</surname><given-names>M</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name></person-group><article-title>Quantitative assessment of the adherence to sublingual immunotherapy</article-title><source>J Allergy Clin Immunol</source><year>2004</year><volume>113</volume><fpage>1219</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">15214362</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marogna</surname><given-names>M</given-names></name><name><surname>Spadolini</surname><given-names>I</given-names></name><name><surname>Massolo</surname><given-names>A</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name><name><surname>Passalacqua</surname><given-names>G</given-names></name></person-group><article-title>Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more</article-title><source>Allergy</source><year>2004</year><volume>59</volume><fpage>1205</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">15461603</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pajno</surname><given-names>GB</given-names></name><name><surname>Vita</surname><given-names>D</given-names></name><name><surname>Caminiti</surname><given-names>L</given-names></name><name><surname>Arrigo</surname><given-names>T</given-names></name><name><surname>Lombardo</surname><given-names>F</given-names></name><name><surname>Incorvaia</surname><given-names>C</given-names></name><name><surname>Barberio</surname><given-names>G</given-names></name></person-group><article-title>Children's compliance with allergen immunotherapy according to administration routes</article-title><source>J Allergy Clin Immunol</source><year>2005</year><volume>116</volume><fpage>1380</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">16337474</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passalacqua</surname><given-names>G</given-names></name><name><surname>Musarra</surname><given-names>A</given-names></name><name><surname>Pecora</surname><given-names>S</given-names></name><name><surname>Amoroso</surname><given-names>S</given-names></name><name><surname>Antonicelli</surname><given-names>L</given-names></name><name><surname>Cadario</surname><given-names>G</given-names></name><name><surname>Di Gioacchino</surname><given-names>M</given-names></name><name><surname>Lombardi</surname><given-names>C</given-names></name><name><surname>Ridolo</surname><given-names>E</given-names></name><name><surname>Sacerdoti</surname><given-names>G</given-names></name><name><surname>Schiavino</surname><given-names>D</given-names></name><name><surname>Senna</surname><given-names>G</given-names></name></person-group><article-title>Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year)</article-title><source>J Allergy Clin Immunol</source><year>2006</year><volume>117</volume><fpage>946</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">16630956</pub-id></element-citation></ref></ref-list></back></article>